KUALA LUMPUR, Feb 27 (Bernama) -- Public-listed healthcare company, Malaysian Genomics Resource Centre Berhad (MGRC), and its subsidiary, pathology services company Clinipath (Malaysia) Sdn Bhd (Clinipath) today announced the availability of affordable, fast-turnaround, liquid biopsy tests developed by CIRCULOGENE Diagnostics LLC for doctors in Malaysia.

Liquid biopsies offer a non-invasive, quick, cheaper and safer, complement to surgical biopsies. They can provide real-time and actionable information about a tumour including which treatments, especially targeted therapies, are available for a particular patient. CIRCULOGENE’s CLIA/CAP-certified liquid biopsy tests examine cell-free nucleic acids to provide full genomic load analysis of somatic and germline mutations, DNA and RNA, and immunotherapy biomarkers all from a single standard tube of blood. This testing enables accurate and real-time data to help doctors and their patients choose the best available targeted therapies and available clinical trials, monitor efficacy and monitor for recurrence.

Conventional tissue biopsies (usually from the primary tumour) are used to determine molecular profiles at a single time point on a single site before targeted therapy commences. CIRCULOGENE’s liquid biopsy test offers what tissue biopsies cannot, the opportunity to take serial samples for longitudinal monitoring of tumour clonal evolution in circulation. “CIRCULOGENE’s liquid biopsy allows doctors to ensure personalised targeted treatment efficacy, monitor drug resistance, metastasis and recurrence, tailoring patients to the right treatment for the right target without delay,” said Dr Chen-Hsiung Yeh, Co-founder and Chief Scientific Officer of CIRCULOGENE. He added, “tumour genome sequencing on circulating cfDNA to guide treatment decisions could be the standard-of-care for new-generation cancer management in the era of precision medicine.”

MGRC and Clinipath continue to work together to make comprehensive pathology services, and the latest in genetic testing available to doctors with a view to improving the lives of patients in Malaysia and the region.

About Malaysian Genomics Resource Centre Berhad

MGRC was a pioneer in genome sequencing, bioinformatics analysis and genetic screening services. Since 2004, MGRC had developed extensive pipelines in the sequencing and analysis of human, animal, plant and microbial genomes for clients worldwide. Today, MGRC is focused on merging the latest in genetic testing with pathology to enable doctors to provide personalised healthcare for their patients.

About Clinipath (Malaysia) Sdn Bhd

Clinipath is one of Malaysia’s largest independent pathology service providers with a nationwide network of 18 branches. It offers a complete range of fast, accurate and reliable pathology testing services. It has been ISO 15189 accredited since 2010. Clinipath is a wholly-owned subsidiary of public-listed MGRC. 

About CIRCULOGENE LLC

Headquartered in Alabama, USA. CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. CIRCULOGENE is Clinical Laboratory Improvement Amendments (CLIA) certified and CAP certified, and provides biomarker testing for a broad range of cancers, allowing physicians to match results to specific drugs and clinical trials. 

Source: Clinipath Malaysia Sdn Bhd

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Shawn Keng
Tel: +6014-9685808
Email: enquiries@mgrc.com.my
 
--BERNAMA